Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Development and Characterization of a Mouse Model for Abdominal Aortic Aneurysm
05:07

Author Spotlight: Development and Characterization of a Mouse Model for Abdominal Aortic Aneurysm

Published on: August 2, 2024

1.6K

Therapeutic Strategies for Abdominal Aortic Aneurysm: A Comprehensive Systematic Review

Egle Kavaliunaite1,2, Joachim Sejr Skovbo Kristensen2,3, Sissel Scheurer4

  • 1Cardiovascular and Renal Research Unit, Institute for Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark.

Journal of Cardiovascular Development and Disease
|December 24, 2025
PubMed
Abstract

Insights

Repurposed drugs like statins and ARBs show promise in reducing abdominal aortic aneurysm (AAA) size in animal models. However, research quality and standardization are crucial for translating these findings to human clinical trials.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Translational Medicine

Background:

  • Abdominal aortic aneurysm (AAA) is a critical condition lacking effective pharmacological treatments.
  • Animal models are used to study AAA pathophysiology and drug efficacy, but clinical translation is challenging.

Purpose of the Study:

  • To systematically review repurposed drugs evaluated in animal models for their impact on AAA progression.
  • To identify drug classes with potential therapeutic benefits for AAA.

Main Methods:

  • Systematic review of 14,127 articles, including 144 studies, adhering to PRISMA guidelines.
  • Drugs classified by Anatomical Therapeutic Chemical (ATC) codes and assessed for effects on AAA diameter in animal models.

Main Results:

  • Cardiovascular, metabolic, and immunomodulatory agents (e.g., statins, ARBs, metformin, rapamycin) demonstrated reduced aneurysm diameter.
  • Significant heterogeneity in study models, treatment timing, and methodological limitations (e.g., lack of blinding) were observed.
  • Potential publication bias may influence the predominance of positive findings.

Conclusions:

  • Drugs showing efficacy after AAA initiation may hold the most clinical promise.
  • Standardized, high-quality preclinical research is essential to advance AAA drug development for human trials.
Keywords:
abdominal aortic aneurysmanimal modelsdrug repurposing

More Related Videos

Manufacturing Abdominal Aorta Hydrogel Tissue-Mimicking Phantoms for Ultrasound Elastography Validation09:32

Manufacturing Abdominal Aorta Hydrogel Tissue-Mimicking Phantoms for Ultrasound Elastography Validation

Published on: September 19, 2018

15.8K
Modified Octopus Technique for Thoracoabdominal Aortic Aneurysm04:56

Modified Octopus Technique for Thoracoabdominal Aortic Aneurysm

Published on: August 1, 2025

444

Related Concept Videos

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
235
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
193
Aneurysm IV: Nursing Management01:22

Aneurysm IV: Nursing Management

Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
350
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
366
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
217
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291